

SCIENTIFIC REPORTS



OPEN

Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an *in vitro* human whole blood study

Received: 04 December 2015

Accepted: 03 March 2016

Published: 22 March 2016

Xia Tao^{1,2}, Stephan Thijssen², Peter Kotanko^{2,3}, Chih-Hu Ho⁴, Michael Henrie⁴, Eric Stroup⁴ & Garry Handelman¹

Protein-bound uraemic toxins (PBUTs) cause various deleterious effects in end-stage kidney disease patients, because their removal by conventional haemodialysis (HD) is severely limited by their low free fraction in plasma. Here we provide an experimental validation of the concept that the HD dialytic removal of PBUTs can be significantly increased by extracorporeal infusion of PBUT binding competitors. The binding properties of indoxyl sulfate (IS), indole-3-acetic acid (IAA) and hippuric acid (HIPA) and their binding competitors, ibuprofen (IBU), furosemide (FUR) and tryptophan (TRP) were studied in uraemic plasma. The effect of binding competitor infusion on fractional removal of PBUT was then quantified in an *ex vivo* single-pass HD model using uraemic human whole blood. The infusion of a combination of IBU and FUR increased the fractional removal of IS from 6.4 ± 0.1 to $18.3 \pm 0.4\%$. IAA removal rose from 16.8 ± 0.3 to $34.5 \pm 0.7\%$. TRP infusion increased the removal of IS and IAA to $10.5 \pm 0.1\%$ and $27.1 \pm 0.3\%$, respectively. Moderate effects were observed on HIPA removal. Pre-dialyzer infusion of PBUT binding competitors into the blood stream can increase the HD removal of PBUTs. This approach can potentially be applied in current HD settings.

With better detection technologies, a broad spectrum of retained solutes in dialysis patients' blood has been identified and characterized in recent studies^{1–4}. This group of solutes is generally defined as uraemic toxins, although toxic effects are not established for all of these compounds. Many of these substances, most notably protein-bound uraemic toxins (PBUTs), interact negatively with biological systems^{5–9}, and reducing the plasma levels of these compounds could improve haemodialysis (HD) outcomes^{7,10}.

The removal of PBUTs is a major challenge for current HD technology. The removal of such solutes in conventional HD primarily relies on diffusion of the free molecules into the dialysate, which is severely limited for PBUTs due to their low free fraction and hence small diffusion gradient. For some strongly bound uraemic toxins, clearance is undetectable during a regular HD session¹¹. Even for many PBUTs where there is detectable dialytic removal, the plasma level of these compounds often remains highly elevated after HD^{10,12–14}.

Several new approaches have been reported in recent publications to improve the dialytic removal of PBUTs. Longer dialysis sessions^{13,14} and hemodiafiltration^{12,15} have only yielded modest improvements. Use of larger dialyzers in combination with higher dialysate flow rate (Qd) of 800 ml/min almost doubled the clearance of indoxyl sulfate (IS)¹³. Fractionated plasma separation and adsorption (FPSA) was 2 times more efficient in removing IS and p-cresol sulfate (PCS) than regular HD in a clinical study¹⁶, although the risk of occlusive thrombosis could be a safety concern for using FPSA for this purpose¹⁷.

Here we propose another innovative method for improving dialytic removal of PBUTs. Our method is based on the observation that albumin-binding ligands can influence the binding properties of albumin to other ligands through direct competition for binding sites, or by allosteric mechanisms^{18–20}. The binding of a given ligand on

¹University of Massachusetts Lowell, Lowell, MA, USA. ²Renal Research Institute, NY, NY, USA. ³Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁴Fresenius Medical Care, Ogden, UT, USA. Correspondence and requests for materials should be addressed to X.T. (email: xia.tao@rriny.com)




Figure 1. IS and PCS displacement in uraemic plasma by furosemide, tryptophan and ibuprofen, determined in static RED assays. Displacer concentration was 1 mmol/l, unless otherwise indicated. IS: indoxyl sulfate; PCS: p-cresol sulfate; IBU: ibuprofen; TRP: tryptophan; FUR: furosemide; PBS: phosphate buffered saline. Bars denote mean, error bars denote standard error of the mean (SEM), N = 3. *P < 0.05, compared to PBS.




Figure 2. HIPA displacement in uraemic plasma by furosemide, tryptophan and ibuprofen, determined in static RED assays. Displacer concentration was 1 mmol/l, unless otherwise indicated. IBU: ibuprofen; TRP: tryptophan; FUR: furosemide; PBS: phosphate buffered saline. Mean \pm SEM, N = 3. *P < 0.05, compared to PBS.

albumin may alter the conformation in the vicinity of the binding sites, or directly block the diffusion path for binding of other ligands. The binding competition between different albumin ligands has been widely reported in the literature^{18,19,21–25}. Using compounds that share the same binding sites as uraemic toxins to impede their binding is a direct approach to increase the free fraction of these uraemic toxins. By infusing binding competitors (displacers) upstream of the dialyzer into the blood compartment, the diffusion gradients and the dialytic removal of PBUTs will be increased. This has been demonstrated *in vitro* using human serum albumin solution²⁶. The purpose of this study was to provide experimental validation of the PBUT displacement approach using human whole blood in an *ex vivo* dialysis model, and to determine whether the presence of red blood cells or endogenous albumin ligands in human plasma has any appreciable impact on the effect of PBUT displacement in comparison to previous *in vitro* studies with human serum albumin.

Results

PBUT displacement in uraemic plasma in a static model system. Ibuprofen, which possesses the highest binding affinity among the displacers tested in the study, increased the free fraction of both IS and PCS approximately 3-fold in uraemic plasma, higher than the free fraction generated by tryptophan (about a 2-fold increase) and furosemide (about a 1.3-fold increase) (Fig. 1). Addition of antipyrine (a negative control), which lacks protein binding capability^{27,28}, did not lead to a significant change in uraemic toxin protein binding (Figs 1 and 2).

L-Tryptophan shares the same primary site as IS and PCS, while furosemide shares the same primary binding site as hippuric acid (HIPA). Thus, tryptophan displaces IS and PCS more efficiently than HIPA (Fig. 1). In contrast, furosemide, which had limited displacement effect on IS and PCS, showed significant displacement of HIPA (Fig. 2).

Dose-response relationship for indoxyl sulfate displacement by ibuprofen, and synergistic effect of ibuprofen and furosemide in normal human plasma in a static dialysis setup. While furosemide alone at a concentration of 0.18 mmol/l did not induce a significant increase in the free fraction of




Figure 3. Dose-response relationships for IS displacement by ibuprofen, and synergistic effect of ibuprofen and furosemide in normal human plasma, determined in static RED assays. Solid circle: ibuprofen with 180 µmol/l furosemide added; open circle: ibuprofen alone. Mean ± SEM, N = 3.




Figure 4. Indoxyl sulfate displacement in human whole blood HD model. Mean ± SEM, N = 3.




Figure 5. Indoleacetic acid displacement in human whole blood HD model. Mean ± SEM, N = 3.

IS (Fig. 1), the same concentration of furosemide was able to boost the IS displacement effect of ibuprofen when given simultaneously, suggesting additive or synergistic effects of these two binding competitors (Fig. 3). The range of ibuprofen concentrations tested in these studies was established based on the plasma level of ibuprofen that could occur with clinically relevant intravenous administration as described in the method section.




Figure 6. Hippuric acid displacement in human whole blood HD model. Mean \pm SEM, N = 3.




Figure 7. Urea extraction ratio in human whole blood HD model. Mean \pm SEM, N = 3.

Effect of displacer infusion on PBUT removal from whole blood in a single-pass haemodialysis model.

Figures 4 and 5 show that a 2.9-fold increase of IS removal and a 2.1-fold increase of indoleacetic acid (IAA) removal were achieved by infusion of ibuprofen and furosemide in an *in vitro* HD model ($P < 0.0001$). Tryptophan infusion was able to increase the removal of IS and IAA by a factor of 1.4 ($P < 0.0001$) and 1.3 ($P < 0.0001$), respectively. HIPA removal, on the other hand, was only slightly increased by infusion of the ibuprofen/furosemide combination, and virtually unaffected by infusion of tryptophan (Fig. 6). Likewise, the urea extraction ratio was unaffected by infusion of binding competitors or phosphate buffered saline (PBS) (Fig. 7). Infusion of PBS as a control did not lead to an increase in removal of any of the PBUTs.

Discussion

To date, more than 90 substances have been reported to accumulate in patients with advanced renal failure^{1,29}. Although the toxicity of many of these substances remains undefined, high levels of IS and PCS have been demonstrated to be associated with damage to multiple systems, such as the kidney^{5,8,9,30}, cardiovascular system^{7,30–32}, smooth muscle^{33,34} and erythrocytes³⁵. AST-120, an oral carbon adsorbent, decreases the plasma levels of colon-derived PBUTs by inhibiting the intestinal absorption of their metabolism precursors, and may slow the rate of loss of renal function, and delay the progression of cardiovascular damage in chronic kidney disease^{31,36,37}. However, overall improvement of dialysis patients' clinical outcomes may require a broader strategy to increase PBUT removal that goes beyond just the colon-derived PBUTs. Increasing the removal of PBUTs during HD could offer an opportunity to significantly improve the poor clinical outcomes and low quality of life that are so prevalent in dialysis patients. This study offers proof of concept that PBUT removal during HD can be substantially increased by infusion of binding competitors upstream of the dialyzer. The approach described here lends itself in principle to routine application during HD. However, we are not advocating the routine application of the displacers used in this proof-of-principle study.

The results from this study are in full agreement with the established knowledge of albumin-ligand binding mechanisms. Albumin is known to be an allosteric protein which changes its conformation following ligand binding^{20,38–41}. Interdependent alterations of albumin binding properties caused by the binding of uraemic toxins,

endogenous substances and drugs have been established^{42–47}. PBUTs vary in their binding sites and binding affinities. Sudlow's site I and II on human albumin have been reported to be the primary binding sites for some protein bound uraemic toxins^{18–20,43–45,47,48}. Within the large family of PBUTs, we chose to study IS as an example of a strongly albumin bound toxin^{18,19,44,45}, IAA as a toxin with medium binding affinity towards albumin^{44,48,49}, and HIPA as an example of a weakly albumin bound toxin^{43–45}. We selected model displacers based on their binding characteristics reported in the literature^{20,24,50–57}, and on data that we collected from our preliminary studies in a static displacement model. Ibuprofen was selected as an example to demonstrate method efficiency with a high affinity displacer, while tryptophan was selected as a low affinity displacer. Furosemide was used to show the effect of a combination of both site I and site II displacers. Feasibility for a proof-of-concept study in humans is another reason we considered when choosing these displacers. Our data demonstrate that strongly bound displacers alter the binding of uraemic toxins on albumin more significantly and result in a higher free fraction of the toxins than displacers with lower albumin binding affinity. It is possible that when the binding of IS at its primary binding site is impeded by site II displacers, its secondary binding site may still be accessible. Thus, a combination of displacers targeting different binding sites can further increase the removal of a given uraemic toxin, as demonstrated in this study. There are conflicting reports in the literature on the primary binding site of HIPA^{43–45}. Our data indicate the primary binding site of HIPA is probably located at Sudlow site I, because the site I displacer furosemide demonstrated greater HIPA displacement from albumin than ibuprofen and tryptophan, whose primary albumin binding site is Sudlow site II.

Considering future clinical applications, we designed our HD model to be compatible with the clinical setup used in the HD clinic. In a clinical HD setting, an infusion pump could be connected between the cannula or catheter and the arterial line. In typical haemodialysis systems, the arterial segment of the blood tubing has a filling volume of about 100 ml, allowing approximately 15 seconds of transit time between the displacer infusion site and the dialyzer at a Qb of 400 ml/min. In our experiments, we connected the displacer infusion upstream of the dialyzer, allowing for 15 seconds of transit time between the infusion site and the dialyzer. Our results show that this time interval is sufficient for the binding and displacement reactions to occur.

We also designed the study to achieve clinically reasonable plasma concentrations of ibuprofen and furosemide. Both of these drugs are commercially available as formulations for intravenous infusion. The concentrations of ibuprofen and furosemide that were targeted in our study are similar to what might be observed clinically with dosing protocols for human subjects consistent with approved rates of infusion for these compounds.

We successfully demonstrated the feasibility of a novel potential therapeutic method of enhancing the removal of highly protein-bound uraemic toxins in HD with the use of displacers. Non-protein-bound substances are not affected by the described displacement method. Of note, we are not advocating the routine clinical use of these particular displacers in a clinical setting. They serve merely as model compounds to demonstrate the concept of displacement therapy for lowering PBUT levels during HD. The primary purpose of this study was to demonstrate the feasibility and efficacy of the PBUT displacement approach in a setting comparable to the one encountered in clinical routine HD. Future clinical pilot trials will be required to document the *in vivo* efficacy of this approach in a clinical HD setting with human subjects. Such trials will also serve to generate important *in vivo* data on PBUT and displacer kinetics for use in mathematical models. Future efforts will also have to focus on identification of suitable displacer substances that are both efficacious and safe for long-term routine clinical use in patients during HD. Our study shows that endogenous molecules, nutritional supplements and high affinity pharmaceutical compounds can all potentially be enlisted in the screening pool for suitable displacer candidates. A displacer molecule should ideally be biologically inert (if not salutary) when used in dialysis patients, as well as effective at displacing PBUTs. The ideal displacer would induce a significant increase in PBUT removal during HD, and yet be rapidly metabolized into biologically inert compounds that are readily removed by HD or eliminated via biliary excretion.

Methods

Materials. Rapid Equilibrium Dialysis (RED) cartridges (8,000 Da molecular weight cut-off) were purchased from Pierce Thermo Fisher (Rockford, IL, USA). Acetonitrile (HPLC grade) was obtained from Fisher Chemical (Thermo Fisher, USA). Furosemide, IAA, HIPA, IS, indole, tryptophan, p-cresol and PBS were obtained from Sigma (St Louis, MO, USA). PCS was synthesized following the protocol of Feigenbaum and Neuberger⁵⁸. Ibuprofen solution (Caldolor injection 100 mg/ml) was obtained from Cumberland Pharmaceuticals Inc. (Nashville, TN, USA). Furosemide was dissolved in 0.05 mol/l sodium hydroxide, and then mixed with Caldolor. The final concentration of ibuprofen was 117 mmol/l and furosemide was 23 mmol/l in the mixture, with a pH of approx. 8.4. Tryptophan infusion solution was prepared by dissolving tryptophan powder in PBS with a final concentration of 50 mmol/l. Acid concentrate (Naturalyte, cat#08-4225-1) and sodium bicarbonate concentrate (Naturalyte sodium bicarbonate concentrate, cat#08-4000-LB) were obtained from Fresenius Medical Care North America (FMCNA, Waltham, MA, USA), and prepared to make complete dialysate, following the manufacturer's instructions. The final pH was adjusted to 7.4. The Envoy 500 clinical analyzer was purchased from Vital Diagnostics (RI, USA). Urea Infinity reagent for Envoy was purchased from Thermo Fisher (Rockford, IL, USA).

Normal human plasma with heparin (from a six-donor pool) was purchased from Bioreclamation (NY, USA, lot# BRH739237). Twenty-four heparinized uraemic plasma samples from 18 HD patients (obtained from a de-identified bio-repository) were pooled to create a uraemic plasma pool. The pooled uraemic plasma contained endogenous (mean \pm SEM, 3 measurements) 23.6 \pm 5.6 μ mol/l tryptophan, 181.9 \pm 6.2 μ mol/l IS, 326.5 \pm 74.1 μ mol/l HIPA and also PCS at a level not quantitated. De-identified human whole blood and informed consent were obtained in cooperation with a local blood bank from healthy volunteer donors (approved by the Ogden Regional Medical Center Institutional Review Board; IRB number 495825-1) on the morning of the experiments. The whole blood was heparinized with 15 IU/ml unfractionated heparin (150,000 USP/l).

All experiments were performed in accordance with relevant guidelines and regulations.




Figure 8. Setup of *in vitro* dialysis model using human whole blood. (A) infusion site of displacers. (B) sample collection site for blood inlet. (C) sample collection site for dialysate outlet. (D) sample collection site for blood outlet.

Dialysis experiments were performed using miniature polysulfone dialyzers produced by the Biotechnology Research Group, Dialyzer R&D, of FMCNA in Ogden, Utah, USA. The specifications of the dialyzers are 0.039 m² surface area with the same pore size distribution as Optiflux® F160NR fibers and 15.5 cm fiber length. Peristaltic pumps (Watson-Marlow 120U) were obtained from Watson-Marlow Fluid Technology Group North America (Wilmington, MA, USA). A syringe pump for the displacer infusion was purchased from Kd Scientific Inc. (Holliston, MA, USA). Plasma and dialysate samples were collected using the Sarstedt S-Monovette® Blood Collection System (EDTA) (Sarstedt AG & Co, Nümbrecht Germany).

Studies of the effect of binding competitors on the albumin binding of PBUTs in uraemic plasma with static dialysis. We evaluated the albumin binding of uraemic toxins and their interaction with displacers in human uraemic plasma utilizing the RED device. Candidate displacers were mixed with uraemic plasma before incubation. The test mixture (300 µl) was added into the sample chamber, while the buffer chamber was filled with 500 µl PBS. After 4 hours of incubation (37 °C, 250 rpm), samples were collected from both chambers for HPLC analysis. The concentration of all displacers and negative control (antipyrine) in the incubations was 1 mmol/l. For furosemide, incubations at final concentration of 0.18 mmol/l were also included since this is the clinically relevant concentration for intravenous administration.

Studies of dose-response effect of ibuprofen and synergistic effect of furosemide and ibuprofen on PBUT displacement in normal human plasma with static dialysis. Normal plasma was spiked with IS (150 µmol/l) and mixed with ibuprofen over a concentration range from 0 to 931 µmol/l to generate a dose-dependent displacement curve using the RED device. Further experiments were performed with the addition of furosemide (final concentration 182 µmol/l), to test the hypothesis that addition of furosemide to ibuprofen would produce greater displacement of IS.

Ibuprofen and furosemide doses were calculated to achieve a range of plasma concentrations that one might encounter when administering these drugs into the extracorporeal circuit following clinical patient-dosing protocols. Infusion of 800 mg ibuprofen into the arterial line over 30 min, with a Q_b of 200 ml/min and a hematocrit of approximately 31%, would result in a plasma concentration of approximately 931 µmol/l. Infusion of 250 mg furosemide over 30 min in this setting would result in a plasma concentration of 182 µmol/l.

Studies of PBUT removal with a haemodialysis model. Dialysis experiments were conducted with a volume of 300 ml of heparinized human whole blood spiked with uraemic toxins, referred to as uraemic blood in the study. IS, IAA and HIPA were added to achieve final plasma concentrations of 150 µmol/l, 15 µmol/l and 400 µmol/l, respectively, except in the experiments with tryptophan as a displacer, where a HIPA concentration of 1 mmol/l was used.

Experiments were conducted at 37 °C, with a Q_b of 12.5 ml/min and counter-current dialysate flow at a Q_d of 25 ml/min. Blood and dialysate were perfused through each compartment in single-pass. An infusion pump was connected between the blood pump and dialyzer blood inlet. The tube segment between the infusion site and the dialyzer blood inlet was 45 cm long, with a 3 mm inner diameter, allowing a 15-second transit time between displacer infusion site and dialyzer inlet.

The system was primed prior to each experiment, initially with saline, and then with “blank” whole blood without uraemic toxins in the blood circuit, and with dialysate in the dialysate circuit. With the blank blood in

recirculation, we manually adjusted the trans-membrane pressure between two circuits so there was zero net ultrafiltration at the beginning of the experiment. Blank whole blood in the circuit was replaced with uraemic blood at the start of the experiments. Details of the experimental model setup are illustrated as in Fig. 8. All experiments were carried out in triplicate.

Human whole blood containing uraemic toxins was circulated for 10 minutes without displacer to measure the baseline uraemic toxin single-pass removal. At 10 min, tryptophan, ibuprofen/furosemide, or PBS were infused into the blood line. The target level of tryptophan was 1 mmol/l in plasma, and 650 $\mu\text{mol/l}$ ibuprofen and 129 $\mu\text{mol/l}$ furosemide in whole blood. The infusion concentrations of ibuprofen and furosemide were determined according to the manufacturer's prescription recommendation as described above. The infusion rate was 70 $\mu\text{l/min}$ for ibuprofen (116 mmol/l) /furosemide (23 mmol/l), 138–150 $\mu\text{l/min}$ for tryptophan (50 mmol/l), and 146 $\mu\text{l/min}$ for PBS.

One milliliter samples for analysis were collected from the dialyzer blood inlet, blood outlet and dialysate outlet at 1-minute intervals throughout the experiment.

Sample analysis for protein-bound uraemic toxins and urea. Blood samples were centrifuged at 13200 rpm for 3 mins. The plasma layer was collected and stored at -80°C . Plasma samples (50 μl) were precipitated with 100 μl of ice-cold acetonitrile to precipitate the proteins. The samples were then vortexed thoroughly and centrifuged at 3000 rpm for 10 minutes. The supernatant, containing the uraemic toxins and displacers, was collected and further diluted 1:1 with deionized water before HPLC injection. The dialysate samples (100 μl) were diluted with 100 μl water before HPLC injection.

Measurements were calibrated with standard curves for all analytes, and were linear over the concentration range of the experiments. Measurements were performed on an Agilent 1100 system (Agilent Technologies, Dover, DE, USA) equipped with a C18 column (Kinetex 5 μm C18 100 \AA , LC Column 150 \times 4.6 mm, Phenomenex, Torrance, CA, USA). Mobile phase A: ammonium formate, 20 mmol/l, pH 4. Mobile phase B: acetonitrile. The gradient profile for mobile phase B was: 0–2 min, 15%; 11–14 min, 100%; 14.2–16 min, 15%; and the flow rate gradient was 0–11.2 min, 0.4 ml/min; 11.2–16 min 0.5 ml/min. The fluorescent detector was programmed with the following timetable: 0–9 min, excitation at 280 nm and emission at 360 nm, for detection of tryptophan and IS; 9–10.5 min, excitation at 214 nm and emission at 309 nm for PCS; and then for the remainder of the HPLC run, excitation at 280 nm and emission at 360 nm, for detection of IAA and ibuprofen. HIPA and furosemide were detected at 230 nm with the UV-Vis detector. The injection volume was 5 μl .

Urea was measured on Envoy clinical biochemical analyzer using Thermo Fisher Infinity urea liquid stable reagent.

Calculation of removal of uraemic toxins and urea from whole blood. PBUT removal from whole blood was expressed as fractional removal, calculated as the amount per unit of time leaving the dialysate outlet, as a percentage of the amount per unit of time entering at the blood inlet, in accordance with

$$\% \text{ uraemic toxin removal} = 100 \cdot (\text{Cdo} \cdot \text{Qd}) / (\text{Cpi} \cdot \text{Qp}), \quad (1)$$

where Cpi and Cdo are the concentrations of each uraemic toxin in the plasma inlet and dialysate outlet streams, respectively. Qd is the dialysate flow rate, and Qp is the plasma flow rate calculated from blood flow rate and hematocrit according to $\text{Qp} = \text{Qb} \cdot (1 - \text{Hct})$. Urea removal was specified as the single pass extraction ratio (ER) in percent, calculated as

$$\text{ER}[\%] = 100 \cdot (\text{Cpi} - \text{Cpo}) / \text{Cpi}, \quad (2)$$

where Cpi and Cpo are the plasma concentrations in the blood inlet and blood outlet streams, respectively.

Statistics. For PBUT displacement in RED assays, Dunnett's post-analysis comparisons to PBS were performed by one way ANOVA using GraphPad Prism (GraphPad Software, La Jolla, CA).

For the PBUT displacement experiments with the HD model, data were converted into the percent change during the intervention phase, compared to the baseline phase for that experiment. After pairing similar observations in the two phases for an individual experiment (minute by minute, pairing baseline phase with intervention phase) and calculating the paired differences, the value for each observation was divided by the corresponding paired difference SD. This transformation created independent observations with theoretically equal variances (within patients and between patients) for the paired differences under the null hypothesis. Each paired t test was two-tailed; a P value less than 0.05 was taken as statistically significant. The data from the first 2 minutes of each phase (baseline and intervention) were excluded to restrict the analysis to data with stable values during that phase. Calculations were done with SPSS 16.0 on an IBM-PC.

References

1. Vanholder, R. *et al.* Review on uremic toxins: Classification, concentration, and interindividual variability. *Kidney Int.* **63**, 1934–1943 (2003).
2. Liabeuf, S., Drüeke, T. B. & Massy, Z. a. Protein-bound uremic toxins: New insight from clinical studies. *Toxins (Basel)*. **3**, 911–919 (2011).
3. Vanholder, R., Glorieux, G., De Smet, R. & Lameire, N. New insights in uremic toxins. *Kidney Int. Suppl.* **63**, S6–S10 (2003).
4. Meijers, B. K. I. *et al.* p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. *Clin. J. Am. Soc. Nephrol.* **4**, 1932–8 (2009).
5. Sun, C.-Y., Chang, S.-C. & Wu, M.-S. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. *PLoS One* **7**, e34026 (2012).
6. Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V. & Glorieux, G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. *J. Am. Soc. Nephrol.* **25**, 1897–907 (2014).

7. Barreto, F. C. *et al.* Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. *Clin. J. Am. Soc. Nephrol.* **4**, 1551–8 (2009).
8. Watanabe, H. *et al.* p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase. *Kidney Int.* **83**, 582–92 (2013).
9. Saito, S. *et al.* Indoxyl sulfate-induced activation of (pro)renin receptor is involved in expression of TGF- β 1 and α -smooth muscle actin in proximal tubular cells. *Endocrinology* **155**, 1899–907 (2014).
10. Marquez, I. O. *et al.* Contribution of residual function to removal of protein-bound solutes in hemodialysis. *Clin. J. Am. Soc. Nephrol.* **6**, 290–6 (2011).
11. Lesaffer, G., De Smet, R., Lameire, N., Dhondt, A., Duym, P. & Vanholder, R. Intradialytic removal of protein-bound uraemic toxins : role of solute characteristics and of dialyser membrane. *Nephrol Dial Transpl.* **15**, 50–57 (2000).
12. Krieter, D. H. *et al.* Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. *Nephrol. Dial. Transplant.* **25**, 212–8 (2010).
13. Sirich, T. L., Luo, F. J. G., Plummer, N. S., Hostetter, T. H. & Meyer, T. W. Selectively increasing the clearance of protein-bound uremic solutes. *Nephrol. Dial. Transplant.* **27**, 1574–1579 (2012).
14. Basile, C. *et al.* Removal of uraemic retention solutes in standard bicarbonate haemodialysis and long-hour slow-flow bicarbonate haemodialysis. *Nephrol. Dial. Transplant.* **26**, 1296–1303 (2011).
15. Meert, N. *et al.* Effective removal of protein-bound uraemic solutes by different convective strategies: A prospective trial. *Nephrol. Dial. Transplant.* **24**, 562–570 (2009).
16. Brettschneider, F. *et al.* Removal of Protein-Bound, Hydrophobic Uremic Toxins by a Combined Fractionated Plasma Separation and Adsorption Technique. *Artif. Organs* **37**, 409–416 (2013).
17. Meijers, B. K. *et al.* Removal of the Uremic Retention Solute p-Cresol Using Fractionated Plasma Separation and Adsorption. *Artif. Organs* **32**, 214–219 (2007).
18. Sakai, T. *et al.* Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. *Pharm. Res.* **18**, 520–524 (2001).
19. Watanabe, H. *et al.* Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin. *Drug Metab. Dispos.* **40**, 1423–1428 (2012).
20. Fanali, G. *et al.* Human serum albumin: From bench to bedside. *Mol. Aspects Med.* **33**, 209–290 (2012).
21. Acta, B., Chemistry, P., Utrecht, G. H. & Utrecht, G. E. *The role of albumin conformation in the binding of diazepam to human serum albumin.* **6**, 2–9 (1980).
22. Sudlow, G., Birkett, D. J. & Wade, D. N. Further characterization of specific drug binding sites on human serum albumin. *Mol. Pharmacol.* **12**, 1052–1061 (1976).
23. Sudlow, G., Birkett, D. J. & Wade, D. N. Characterization of two specific drug binding sites on human serum albumin. *Mol. Pharmacol.* **11**, 824–832 (1975).
24. Kansy, M., Gerber, P. R., Kratochwil, N. a, Huber, W. & Mu, F. Predicting plasma protein binding of drugs : a new approach. *Biochem. Pharmacol.* **64**, 1355–1374 (2002).
25. Grudniewska, A., Gniłka, R. & Wawrzęńczyk, C. Ligand Binding Strategies of Human Serum Albumin:How Can the Cargo be Utilized? *Chirality* **22**, 929–935 (2010).
26. Tao, X., Thijssen, S., Levin, N., Kotanko, P. & Handelman, G. Enhanced Indoxyl Sulfate Dialyzer Clearance with the Use of Binding Competitors. *Blood Purif.* **39**, 323–330 (2015).
27. Fraser, H. S., Mucklow, J. C., Murray, S. & Davies, D. S. Assessment of antipyrene kinetics by measurement in saliva. *Br. J. Clin. Pharmacol.* **3**, 321–325 (1976).
28. Mehta, M. U. *et al.* Antipyrene kinetics in liver disease and liver transplantation. *Clin. Pharmacol. Ther.* **39**, 372–377 (1986).
29. Duranton, F. *et al.* Normal and pathologic concentrations of uremic toxins. *J. Am. Soc. Nephrol.* **23**, 1258–70 (2012).
30. Yu, M., Kim, Y. J. & Kang, D.-H. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. *Clin. J. Am. Soc. Nephrol.* **6**, 30–9 (2011).
31. Fujii, H. *et al.* Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. *Nephrol. Dial. Transplant* **24**, 2089–95 (2009).
32. Lekawanvijit, S. *et al.* Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? *Eur. Heart J.* **31**, 1771–9 (2010).
33. Muteliefu, G., Enomoto, A., Jiang, P., Takahashi, M. & Niwa, T. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. *Nephrol. Dial. Transplant* **24**, 2051–8 (2009).
34. Chitalia, V. C. *et al.* Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. *Circulation* **127**, 365–376 (2013).
35. Ahmed, M. S., Abed, M., Voelkl, J. & Lang, F. Triggering of suicidal erythrocyte death by uremic toxin indoxyl sulfate. *BMC Nephrol.* **14**, 244; doi: 10.3390/toxins6010054 (2013).
36. Schulman, G., Vanholder, R. & Niwa, T. AST-120 for the management of progression of chronic kidney disease. *Int. J. Nephrol. Renovasc. Dis.* **7**, 49–56 (2014).
37. Hatakeyama, S. *et al.* Effect of an oral adsorbent, AST-120, on dialysis initiation and survival in patients with chronic kidney disease. *Int. J. Nephrol.* **2012**, 376128; doi: 10.1155/2012/376128 (2012).
38. Ascenzi, P. & Fasano, M. Serum heme-albumin: An allosteric protein. *IUBMB Life* **61**, 1118–1122 (2009).
39. Ascenzi, P. *et al.* Allosteric modulation of drug binding to human serum albumin. *Mini Rev. Med. Chem.* **6**, 483–489 (2006).
40. Bojko, B. *et al.* Alterations of furosemide binding to serum albumin induced by increased level of fatty acid. *J. Pharm. Biomed. Anal.* **51**, 273–277 (2010).
41. Zenei, T. & Hiroshi, T. Specific and non-specific ligand binding to serum albumin. *Biochem. Pharmacol.* **34**, 1999–2005 (1985).
42. Takamura, N., Maruyama, T. & Otagiri, M. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: Possible mechanism of the binding defect in uremia. *Clin. Chem.* **43**, 2274–2280 (1997).
43. Zaidi, N., Ajmal, M. R., Rabbani, G., Ahmad, E. & Khan, R. H. A Comprehensive insight into binding of hippuric acid to human serum albumin: A study to uncover its impaired elimination through hemodialysis. *PLoS One* **8**, e71422; doi: 10.1371/journal.pone.0071422 (2013).
44. Sakai, T., Takadate, A. & Otagiri, M. Characterization of binding site of uremic toxins on human serum albumin. *Biol. Pharm. Bull.* **18**, 1755–1761 (1995).
45. Sarnatskaya, V. V. *et al.* Effect of protein-bound uraemic toxins on the thermodynamic characteristics of human albumin. *Biochem. Pharmacol.* **63**, 1287–1296 (2002).
46. Zaidi, N. *et al.* Biophysical insight into furosemide binding to human serum albumin: A study to unveil its impaired albumin binding in uremia. *J. Phys. Chem. B* **117**, 2595–2604 (2013).
47. Meijers, B. K. I., Bammens, B., Verbeke, K. & Evenepoel, P. A Review of Albumin Binding in CKD. *Am. J. Kidney Dis.* **51**, 839–850 (2008).
48. Šoškić, M. & Magnus, V. Binding of ring-substituted indole-3-acetic acids to human serum albumin. *Bioorganic Med. Chem.* **15**, 4595–4600 (2007).
49. Conrad, M. L., Moser, A. C. & Hage, D. S. Evaluation of indole-based probes for high-throughput screening of drug binding to human serum albumin : analysis by high-performance. *J Sep Sci.* **32**, 1145–1155 (2009).

50. Di Masi, A. *et al.* Ibuprofen binding to secondary sites allosterically modulates the spectroscopic and catalytic properties of human serum heme-albumin. *FEBS J.* **278**, 654–662 (2011).
51. Cheruvallath, V. K., Riley, C. M., Narayanan, S. R., Lindenbaum, S. & Perrin, J. H. A quantitative circular dichroic investigation of the binding of the enantiomers of ibuprofen and naproxen to human serum albumin. *J. Pharm. Biomed. Anal.* **15**, 1719–1724 (1997).
52. Yamasaki, K., Chuang, V. T. G., Maruyama, T. & Otagiri, M. Albumin-drug interaction and its clinical implication. *Biochim. Biophys. Acta-Gen. Subj.* **1830**, 5435–5443 (2013).
53. McMenamy, R. H. & Oncley, J. L. The specific binding of L-tryptophan to serum albumin. *J. Biol. Chem.* **233**, 1436–1447 (1958).
54. Cunningham, V. J., Hay, L. & Stoner, H. B. The binding of L-tryptophan to serum albumins in the presence of non-esterified fatty acids. *Biochem J* **146**, 653–658 (1975).
55. Kragh-Hansen, U. Relations between high-affinity binding sites for L-tryptophan, diazepam, salicylate and Phenol Red on human serum albumin. *Biochem. J.* **209**, 135–142 (1983).
56. Takamura, N., Maruyama, T. & Otagiri, M. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: Possible mechanism of the binding defect in uremia. *Clin. Chem.* **43**, 2274–2280 (1997).
57. Viani, A., Cappiello, M., Silvestri, D. & Pacifici, G. M. Binding of furosemide to albumin isolated from human fetal and adult serum. *Dev. Pharmacol. Ther.* **16**, 33–40 (1991).
58. Feigenbaum, J. & Neuberg, C. A. Simplified Method for the preparation of aromatic sulfuric acid esters. *Notes* **63**, 3529–3530 (1941).

Acknowledgements

We thank Dr. Douglas Y. Rowland and Mrs. Hanjie Zhang for their advice on statistical analysis.

Author Contributions

X.T. wrote the manuscript. All experiments were conducted by X.T., S.T. and M.H.; P.K., C.-H.H., E.S. and G.H. reviewed and revised the manuscript.

Additional Information

Competing financial interests: Xia Tao, Stephan Thijssen and Peter Kotanko are employees of Renal Research Institute, affiliated with Fresenius Medical Care North America (FMCNA). Peter Kotanko holds stock of FMCNA. Peter Kotanko is an inventor on a U.S. patent (assigned to FMCNA) on the method described in the paper. Chih-Hu Ho, Michael Henrie and Eric Stroup are employees of FMCNA. Garry Handelman declares no conflicts of interest.

How to cite this article: Tao, X. *et al.* Improved dialytic removal of protein-bound uraemic toxins with use of albumin binding competitors: an *in vitro* human whole blood study. *Sci. Rep.* **6**, 23389; doi: 10.1038/srep23389 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>